Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia

Blood

Volumn 107, Issue 9, 2006, Pages 3469-3473

  Estey, Elihu ^a,b   Garcia Manero, Guillermo ^a   Ferrajoli, Alessandra ^a   Faderl, Stefan ^a   Verstovsek, Srdan ^a   Jones, Dan ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; GEMTUZUMAB OZOGAMICIN; RETINOIC ACID;

ADULT; ARTICLE; CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLOW UP; HEART ARRHYTHMIA; HUMAN; LEUKOCYTE COUNT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QT PROLONGATION; RECURRENT DISEASE; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 33646386643     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-10-4006     Document Type: Article

References (19)

1. Soignet S, Frankel S, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:3852-3860.
2. Jurcic J, DeBlasio T, Dumont L, Yao T-J, Scheinberg D. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res. 2000:6:372-380.
3. George B, Mathews V, Vishwabandhya A, Srivastava A, Chandy M. Arsenic trioxide in the treatment of patients with newly diagnosed acute promyelocytic leukemia: toxicity and outcome [abstract]. Blood. 2004;104:254a.
4. Gavamzadeh A, Alimoghaddam K, Ghaffari H, et al. Treatment of new cases of acute promyelocytic leukaemia by arsenic trioxide [abstract]. Blood. 2004;104:116a.
5. Shen Z-X, Shi Z-Z, Fang J, et al. All-transretinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004;101:5328-5335.
6. Estey E, Giles F, Beran M, et al. Experience with gemtuzumab ozogamicin ("mylotarg") + all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood. 2002;99:4222-4224.
7. Lo-Coco F, Cimino G, Breccia M, et al. Gentuzumab ozogamicin ("mylotarg") as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood. 2004;104:1995-1999.
8. Estey E, Koller C, Tsimberidou A, et al. Potential curability of newly diagnosed acute promyelocytic leukemia without chemotherapy: the example of liposomal all-trans retinoic acid. Blood. 2005;105:1366-1367.
9. Dyck JA, Warrell RP, Evans RM, Miller WH Jr. Rapid diagnosis of acute promyelocytic leukemia by immunohistochemical localization of PML/RAR-α protein. Blood. 1995;86:862-867.
10. Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96:1247-1253.
11. Thall P, Simon R, Estey, E. New statistical strategy for monitoring safety and efficacy in single arm clinical trials. J Clin Oncol. 1996:14:296-303.
12. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia: the European APL Group. Blood. 1999;94:1192-1200.
13. Burnett A, Grimwade D, Solomon E, Wheatley K, Goldstone A. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: results of the randomized MRC trial. Blood. 1999;93:4131-4143.
14. Sanz M, Vallenga E, Rayon C, et al. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood. 2004:104:3490-3493.
15. Ades L, Chevret S, De Botton S, et al, for the European APL Group. Outcome of acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy in elderly patients: the European group experience. Leukemia 2005;19:230-233.
16. Fenaux P, Chevret S, De Botton S. Treatment of older adults with acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2003;16:495-501.
17. LoCoco F, Breccia M, Diverio D. The importance of molecular monitoring in acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2003;16:503-520.
18. Sanz M, Martín G, González M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004;103:1237-1243.
19. Lo Coco F, Avvisati G, Vignetti M, et al. Frontline treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation: results of the AIDA 2000 trial of the Italian GIMEMA group [abstract]. Blood. 2004;104:115a.